Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Firibastat - Quantum Genomics

Next Previous
Drug Profile

Firibastat - Quantum Genomics

Alternative Names: Amino butane sulfonate disulfure; QGC 001; QGC-011; RB 150

Latest Information Update: 02 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CNRS; INSERM; University Paris Descartes
  • Developer Quantum Genomics
  • Class Amines; Aminopeptidases; Antihypertensives; Cardiovascular therapies; Disulfides; Heart failure therapies; Metalloexopeptidases; Small molecules; Sulfonic acids
  • Mechanism of Action Glutamyl aminopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Hypertension
  • Phase II Chronic heart failure; Left ventricular dysfunction

Most Recent Events

  • 02 Dec 2024 No development reported - Phase-III for Hypertension in Hungary, Bulgaria, Canada, Bulgaria, Poland, USA, Germany, Spain, France, Czech Republic (PO) (NCT04277884) (Quantum Genomics pipeline, December 2024)
  • 17 Jan 2023 Quantum Genomics terminates the phase III trial for Hypertension (Treatment-resistant) in USA, Slovakia, Spain, Hungary and Canada (PO) due to no efficacy demonstrated in the QGC001-3QG1 study (EudraCT2021-001404-14) (NCT04857840)
  • 20 Sep 2022 Quantum Genomics completes a phase-III clinical trials in Hypertension in Bulgaria, Czech Republic, France, Germany, Hungary, Poland, Spain, USA (PO) (EudraCT2019-004509-29, NCT04277884)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top